Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITAL Heart Failure Ancillary Study
NCT02271230Phase 3Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Aug 2014
- Primary completion
- Dec 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omega-3-acid triglycerides and vitamin d in heart failure (HF) (4 arms), sponsored by Brigham and Women's Hospital. Primary endpoint: Number of Participants With New Heart Failure Hospitalization at 5 years. Started Aug 2014; status: completed.
02
Drugs
omega-3-acid triglyceridesvitamin d
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT02271230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02271230.